We are live on ! Find out more
AVA

Atlas Venture Advisors Portfolio holdings

AUM $122M
1-Year Est. Return 26.28%
This Fund
S&P 500
This Quarter Est. Return
-0.8%
1 Year Est. Return
-26.28%
3 Year Est. Return
-22.79%
5 Year Est. Return
-46.44%
10 Year Est. Return
–
AUM
$963M
AUM Growth
+$422M
Cap. Flow
+$458M
Cap. Flow %
47.58%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
IAS
Integral Ad Science
IAS
+$468M

Top Sells

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$9.22M

Sector Composition

Rank Sector Weight
1 Communication Services 53.03%
2 Consumer Discretionary 39.44%
3 Healthcare 7.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IAS
1
DELISTED
Integral Ad Science
IAS
$468M 48.54%
+22,722,770
New +$468M
DKNG icon
2
DraftKings
DKNG
$11.4B
$380M 39.44%
7,284,008
– –
TBIO
3
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$51.6M 5.35%
1,872,115
– –
ROKU icon
4
Roku
ROKU
$21.1B
$26.5M 2.75%
57,707
– –
SNAP icon
5
Snap
SNAP
$7.32B
$16.7M 1.74%
245,559
– –
BCYC
6
Bicycle Therapeutics
BCYC
$270M
$9.34M 0.97%
307,696
-305,000
-50% -$9.22M
FSTX
7
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$4.94M 0.51%
574,996
– –
VRDN icon
8
Viridian Therapeutics
VRDN
$2.13B
$3.83M 0.4%
209,505
– –
LRMR icon
9
Larimar Therapeutics
LRMR
$416M
$2.87M 0.3%
292,184
– –

Similar funds

RCWM
Red Crane Wealth Management San Francisco, California $122M AUM 14.77% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SO
Sierra Ocean Ripon, California $122M AUM 16.19% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return
TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Atlas Venture Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Atlas Venture Advisors held 9 positions worth $963M, up 78% from $542M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Advisors deployed $458M of net new capital in Q2 2021, opening 1 new position. Its largest new stake was Integral Ad Science: 22,722,770 shares worth $468M.

By sector, the portfolio is most concentrated in Communication Services at 53% of assets, up from 5.8% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Bicycle Therapeutics, an estimated $9.22M trimmed.

  • Atlas Venture Advisors's largest Q2 2021 buy was Integral Ad Science: 22,722,770 shares worth $468M.
  • Atlas Venture Advisors's biggest Q2 2021 reduction was Bicycle Therapeutics, cutting an estimated $9.22M.
  • Atlas Venture Advisors's ten largest holdings make up 100% of its $963M portfolio in Q2 2021.
  • Atlas Venture Advisors opened 1 new position and closed 0 in Q2 2021.
  • Atlas Venture Advisors's portfolio value rose 78% quarter-over-quarter to $963M.

Based on Atlas Venture Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.